AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Jazz Pharmaceuticals, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SNW8K1
214.00▼ 0.65 (-0.30%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
214.65
Day's Range
211.49 – 215.35
52-Week Range
128.80 – 266.38
Volume
535.0K
Avg Volume
796.9K
Share Statistics
Shares Outstanding
Employees
2,890
Exchange
XNAS
Listed
2007-06-01
Share count as of July 27, 2026

Jazz Pharmaceuticals, Inc. (JAZZ) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Jazz Pharmaceuticals, Inc. (JAZZ)
What is Jazz Pharmaceuticals, Inc.'s Market Cap?
Jazz Pharmaceuticals, Inc.'s Market Cap is $13.9B, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s Enterprise Value?
Jazz Pharmaceuticals, Inc.'s Enterprise Value is $16.6B, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s Trailing P/E?
Jazz Pharmaceuticals, Inc.'s Trailing P/E is 14.8×, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s Price / Sales?
Jazz Pharmaceuticals, Inc.'s Price / Sales is 3.0×, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s EV / Revenue?
Jazz Pharmaceuticals, Inc.'s EV / Revenue is 3.6×, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s EV / EBITDA?
Jazz Pharmaceuticals, Inc.'s EV / EBITDA is 17.7×, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s Revenue (TTM)?
Jazz Pharmaceuticals, Inc.'s Revenue (TTM) is $4.6B, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s Net Income (TTM)?
Jazz Pharmaceuticals, Inc.'s Net Income (TTM) is $940.8M, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s EBITDA?
Jazz Pharmaceuticals, Inc.'s EBITDA is $938.5M, based on as-reported figures from SEC (XBRL) filings.
What is Jazz Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
Jazz Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 14.49, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · JAZZAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+15.5%+19.1%+10.1%+6.7%
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)
Selling, general and administrative
Research and development
Intangible asset amortization
Acquired in-process research and development—
Gain on sale of priority review voucher——
Total operating expenses
% of revenue79.5%68.5%78.8%94.9%
Income (loss) from operations
% of revenue20.5%31.5%21.2%5.1%
Interest expense, net
Foreign exchange gain (loss)
Income (loss) before income tax expense (benefit) and equity in loss of investees
Income tax expense (benefit)
Equity in loss of investees
Net income (loss)
% of revenue16.0%27.4%17.0%22.3%
Basic (in dollars per share)
Diluted (in dollars per share)